Publications

Export 193 results:
Sort by: Author Title Type [ Year (Desc)]
Filters: Author is Fox, Keith A A  [Clear All Filters]
2013
Lucking AJ, Gibson KR, Paterson EE, Faratian D, Ludlam CA, Boon NA, et al. Endogenous tissue plasminogen activator enhances fibrinolysis and limits thrombus formation in a clinical model of thrombosis. Arterioscler Thromb Vasc Biol. 2013;33(5):1105-11. Abstract
Fox KA. Dual or single antiplatelet therapy with anticoagulation? Lancet. 2013;381(9872):1080-1.
Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, et al. Outcomes Following Cardioversion and Atrial Fibrillation Ablation in Patients Treated with Rivaroxaban and Warfarin in the ROCKET AF Trial. J Am Coll Cardiol. 2013. Abstract
Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross TJ, Drozda JP, et al. 2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease: . Circulation. 2013.
Cannon CP, Brindis RG, Chaitman BR, Cohen DJ, Cross TJ, Drozda JP, et al. 2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease: . J Am Coll Cardiol. 2013.
Piccini JP, Stevens SR, Chang Y, Singer DE, Lokhnygina Y, Go AS, et al. Renal Dysfunction as a Predictor of Stroke and Systemic Embolism in Patients With Nonvalvular Atrial Fibrillation: Validation of the R2CHADS2 Index in the ROCKET AF and ATRIA Study Cohorts. Circulation. 2013;127(2):224-32. Abstract
Steg G, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, et al. Grupo de Trabajo para el manejo del infarto agudo de miocardio con elevación del segmento ST de la Sociedad Europea de Cardiología (ESC). Rev Esp Cardiol. 2013;66(1):53.e1-53.e46.
Fox KA, Simpson IA, Lüscher TF. The Year in Cardiology series: the most recent advances in a nutshell for the readers of the European Heart Journal. Eur Heart J. 2013;34(4):307.
Patel MR, Hellkamp AS, Lokhnygina Y, Piccini JP, Zhang Z, Mohanty S, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial . J Am Coll Cardiol. 2013;61(6):651-8. Abstract
Huber K, Goldstein P, Danchin N, Fox KA, Welsh R, Granger CB, et al. Enhancing the efficacy of delivering reperfusion therapy: A European and North American experience with ST-segment elevation myocardial infarction networks. Am Heart J. 2013;165(2):123-32. Abstract
Woudstra P, Grundeken MJ, van de Hoef TP, Wallentin L, Fox KA, de Winter RJ, et al. Prognostic relevance of PCI-related myocardial infarction. Nat Rev Cardiol. 2013;10(4):231-6. Abstract
Japp AG, Chelliah R, Tattersall L, Lang NN, Meng X, Weisel K, et al. Effect of PSI-697, a Novel P-Selectin Inhibitor, on Platelet-Monocyte Aggregate Formation in Humans. J Am Heart Assoc. 2013;2(1):e006007. Abstract
Singer DE, Hellkamp AS, Piccini JP, Mahaffey KW, Lokhnygina Y, Pan G, et al. Impact of Global Geographic Region on Time in Therapeutic Range on Warfarin Anticoagulant Therapy: Data From the ROCKET AF Clinical Trial. J Am Heart Assoc. 2013;2(1):e000067. Abstract
2012
Simms AD, Reynolds S, Pieper K, Baxter PD, Cattle BA, Batin PD, et al. Evaluation of the NICE mini-GRACE risk scores for acute myocardial infarction using the Myocardial Ischaemia National Audit Project (MINAP) 2003-2009: National Institute for Cardiovascular Outcomes Research (NICOR). Heart. 2012. Abstract
Alam SR, Shah AS, Richards J, Lang NN, Barnes G, Joshi N, et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circ Cardiovasc Imaging. 2012;5(5):559-65. Abstract
Alam SR, Shah AS, Richards J, Lang NN, Barnes G, Joshi N, et al. Ultrasmall superparamagnetic particles of iron oxide in patients with acute myocardial infarction: early clinical experience. Circ Cardiovasc Imaging. 2012;5(5):559-65. Abstract
Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J. 2012;33(17):2143-50. Abstract
Bhatt DL, Paré G, Eikelboom JW, Simonsen KL, Emison ES, Fox KA, et al. The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J. 2012;33(17):2143-50. Abstract
Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297-309. Abstract
Fox KA. COURAGE or FAME...? Who should have percutaneous coronary intervention in stable coronary artery disease? Heart. 2012.
Fox KA. COURAGE or FAME...? Who should have percutaneous coronary intervention in stable coronary artery disease? Heart. 2012.
Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J. 2012;33(20):2569-619.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551-67.
Gurbel PA, Erlinge D, Ohman ME, Neely B, Neely M, Goodman SG, et al. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012;308(17):1785-94. Abstract
Gurbel PA, Erlinge D, Ohman ME, Neely B, Neely M, Goodman SG, et al. Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization: The TRILOGY ACS Platelet Function Substudy. JAMA. 2012:1-10. Abstract